| CIREX | KTRIX | CIREX / KTRIX | |
| Total Expense Ratio | 0.84 | 0.67 | 125% |
| Annual Report Gross Expense Ratio | 0.84 | 0.67 | 125% |
| Fund Existence | 24 years | 31 years | - |
| Gain YTD | 9.382 | 7.752 | 121% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 250 | 1000000 | 0% |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 128B | 623M | 20,546% |
| Annual Yield % from dividends | 2.49 | 4.33 | 58% |
| Returns for 1 year | 10.00 | 9.94 | 101% |
| Returns for 3 years | 38.31 | 21.19 | 181% |
| Returns for 5 years | 41.46 | 6.34 | 654% |
| Returns for 10 years | 89.81 | 55.03 | 163% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BVEIX | 23.23 | 0.16 | +0.69% |
| Becker Equity Fund Institutional | |||
| LRSTX | 23.80 | 0.04 | +0.17% |
| Lord Abbett Small Cap Value R5 | |||
| RGBBX | 42.03 | -0.01 | -0.02% |
| American Funds Global Balanced R-2 | |||
| FTDZX | 206.97 | -0.73 | -0.35% |
| Franklin Biotechnology Discovery Adv | |||
| GAGPX | 13.21 | -0.35 | -2.58% |
| Goldman Sachs Em Mkts Eq Insghts P | |||